This study will evaluate the efficacy and safety of GDC-0077 plus palbociclib and fulvestrant versus a placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor positive, HER2-negative, locally advanced or metastatic breast cancer.

Who is the trial for? Women or men with confirmed hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer; confirmed biomarker PIK3CA mutation; they must have progressed during adjuvant treatment or within 12 months of completing endocrine therapy. Patients with bone only disease or history of type 1 or 2 diabetes are excluded.

New Zealand sites for this trial are: Auckland City Hospital, Waikato Hospital, Palmerston North Hospital and Christchurch Hospital. Recruitment has now closed at the Palmerston  North site (April 2024). Please ask your doctor or medical team if you are interested in participating in this trial.

More trial information is available here.

29 April 2024